Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1030

1.

Protocol update for the SABATO trial: a randomized controlled trial to assess early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection.

Kaasch AJ, Rommerskirchen A, Hellmich M, Fätkenheuer G, Prinz-Langenohl R, Rieg S, Kern WV, Seifert H; SABATO trial group.

Trials. 2020 Feb 12;21(1):175. doi: 10.1186/s13063-020-4102-0.

2.

A behavioural approach to specifying interventions: what insights can be gained for the reporting and implementation of interventions to reduce antibiotic use in hospitals?

Duncan EM, Charani E, Clarkson JE, Francis JJ, Gillies K, Grimshaw JM, Kern WV, Lorencatto F, Marwick CA, McEwen J, Möhler R, Morris AM, Ramsay CR, Rogers Van Katwyk S, Rzewuska M, Skodvin B, Smith I, Suh KN, Davey PG.

J Antimicrob Chemother. 2020 Feb 4. pii: dkaa001. doi: 10.1093/jac/dkaa001. [Epub ahead of print]

PMID:
32016346
3.

A clinical predictive model of multidrug resistance in neutropenic cancer patients with bloodstream infection due to Pseudomonas aeruginosa (IRONIC study).

Gudiol C, Albasanz-Puig A, Laporte-Amargós J, Pallarès N, Mussetti A, Ruiz-Camps I, Puerta-Alcalde P, Abdala E, Oltolini C, Akova M, Montejo M, Mikulska M, Martín-Dávila P, Herrera F, Gasch O, Drgona L, Paz Morales H, Brunel AS, García E, Isler B, Kern WV, Morales I, Maestro-de la Calle G, Montero M, Kanj SS, Sipahi OR, Calik S, Márquez-Gómez I, Marin JI, Gomes MZR, Hemmatti P, Araos R, Peghin M, Del Pozo JL, Yáñez L, Tilley R, Manzur A, Novo A, Carratalà J; IRONIC study group.

Antimicrob Agents Chemother. 2020 Feb 3. pii: AAC.02494-19. doi: 10.1128/AAC.02494-19. [Epub ahead of print]

PMID:
32015035
4.

The combination of WGS and RNA-Seq is superior to conventional diagnostic tests in multiple myeloma: Ready for prime time?

Höllein A, Twardziok SO, Walter W, Hutter S, Baer C, Hernandez-Sanchez JM, Meggendorfer M, Haferlach T, Kern W, Haferlach C.

Cancer Genet. 2020 Jan 11. pii: S2210-7762(19)30521-6. doi: 10.1016/j.cancergen.2020.01.001. [Epub ahead of print]

5.

Detection of High-Level Rifaximin Resistance in Enteric Bacteria by Agar Screen.

Baumert PMP, Camp J, Gölz H, Vavra M, Schuster S, Kern WV, Mischnik A; DZIF-ATHOS Study Group.

Microb Drug Resist. 2019 Dec 19. doi: 10.1089/mdr.2019.0295. [Epub ahead of print]

PMID:
31855490
6.

[Toxicity of quinolone antibiotics - new untoward effects and reevaluation of known side effects].

Kern WV.

Dtsch Med Wochenschr. 2019 Dec;144(24):1697-1702. doi: 10.1055/a-0899-2883. Epub 2019 Dec 2. German.

PMID:
31791074
7.

Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis.

Dill V, Kauschinger J, Hauch RT, Buschhorn L, Odinius TO, Müller-Thomas C, Mishra R, Kyncl MC, Schmidt B, Prodinger PM, Hempel D, Bellos F, Höllein A, Kern W, Haferlach T, Slotta-Huspenina J, Bassermann F, Peschel C, Götze KS, Waizenegger IC, Höckendorf U, Jost PJ, Jilg S.

Eur J Haematol. 2020 Feb;104(2):125-137. doi: 10.1111/ejh.13354. Epub 2019 Dec 8.

PMID:
31758597
8.

Psychiatric Presentation of Anti-NMDA Receptor Encephalitis.

Endres D, Rauer S, Kern W, Venhoff N, Maier SJ, Runge K, Süß P, Feige B, Nickel K, Heidt T, Domschke K, Egger K, Prüss H, Meyer PT, Tebartz van Elst L.

Front Neurol. 2019 Nov 5;10:1086. doi: 10.3389/fneur.2019.01086. eCollection 2019.

9.

Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations.

Höllein A, Nadarajah N, Meggendorfer M, Jeromin S, Kern W, Haferlach C, Haferlach T.

Hemasphere. 2019 Feb 4;3(1):e178. doi: 10.1097/HS9.0000000000000178. eCollection 2019 Feb.

10.

Molecular characterization of a second myeloid neoplasm developing after treatment for acute myeloid leukemia.

Hartmann L, Nadarajah N, Meggendorfer M, Höllein A, Vetro C, Kern W, Haferlach T, Haferlach C, Stengel A.

Leukemia. 2019 Nov 12. doi: 10.1038/s41375-019-0633-3. [Epub ahead of print]

PMID:
31719678
11.

Burden of bacterial bloodstream infection-a brief update on epidemiology and significance of multidrug-resistant pathogens.

Kern WV, Rieg S.

Clin Microbiol Infect. 2020 Feb;26(2):151-157. doi: 10.1016/j.cmi.2019.10.031. Epub 2019 Nov 9. Review.

PMID:
31712069
12.

Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia.

Vetro C, Haferlach T, Meggendorfer M, Stengel A, Jeromin S, Kern W, Haferlach C.

Cancer Genet. 2020 Jan;240:15-22. doi: 10.1016/j.cancergen.2019.10.006. Epub 2019 Nov 1.

PMID:
31698332
13.

Bacterial bloodstream infection.

Allerberger F, Kern WV.

Clin Microbiol Infect. 2020 Feb;26(2):140-141. doi: 10.1016/j.cmi.2019.10.004. Epub 2019 Oct 12. No abstract available.

PMID:
31614195
14.

Contribution of specific pathogens to bloodstream infection mortality in neutropenic patients with hematologic malignancies: Results from a multicentric surveillance cohort study.

Kern WV, Roth JA, Bertz H, Götting T, Dettenkofer M, Widmer AF, Theilacker C; Hospital Infection Surveillance System for Patients with Hematologic/Oncologic Malignancies Study Group (ONKO-KISS).

Transpl Infect Dis. 2019 Dec;21(6):e13186. doi: 10.1111/tid.13186. Epub 2019 Nov 1.

PMID:
31574202
15.

Issue Highlights - September 2019.

Kern W.

Cytometry B Clin Cytom. 2019 Sep;96(5):335-337. doi: 10.1002/cyto.b.21848. No abstract available.

PMID:
31566911
16.

Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials.

Lathouwers E, Wong EY, Brown K, Baugh B, Ghys A, Jezorwski J, Mohsine EG, Van Landuyt E, Opsomer M, De Meyer S; AMBER and EMERALD Study Groups.

AIDS Res Hum Retroviruses. 2020 Jan;36(1):48-57. doi: 10.1089/AID.2019.0111. Epub 2019 Oct 21.

17.

Physical Foaming and Crosslinking of Polyethylene with Modified Talcum.

Kaltenegger-Uray A, Rieß G, Lucyshyn T, Holzer C, Kern W.

Polymers (Basel). 2019 Sep 9;11(9). pii: E1472. doi: 10.3390/polym11091472.

18.

Clinimetric properties and suitability of selected quality indicators for assessing antibiotic use in hospitalized adults: a multicentre point prevalence study in 24 hospitals in Germany.

Först G, Kern WV, Weber N, Querbach C, Kleideiter J, Knoth H, Hagel S, Ambrosch A, Löbermann M, Schröder P, Borde J, Steib-Bauert M, de With K; ABS-QI Study Group .

J Antimicrob Chemother. 2019 Dec 1;74(12):3596-3602. doi: 10.1093/jac/dkz364.

PMID:
31504603
19.

Dark-matter matters: Discriminating subtle blood cancers using the darkest DNA.

Parida L, Haferlach C, Rhrissorrakrai K, Utro F, Levovitz C, Kern W, Nadarajah N, Twardziok S, Hutter S, Meggendorfer M, Walter W, Baer C, Haferlach T.

PLoS Comput Biol. 2019 Aug 30;15(8):e1007332. doi: 10.1371/journal.pcbi.1007332. eCollection 2019 Aug.

20.

Organization and training at national level of antimicrobial stewardship and infection control activities in Europe: an ESCMID cross-sectional survey.

Maraolo AE, Ong DSY, Cimen C, Howard P, Kofteridis DP, Schouten J, Mutters NT, Pulcini C; ESGAP-EUCIC-TAE Working Group on AMS/IPC mapping in Europe.

Eur J Clin Microbiol Infect Dis. 2019 Nov;38(11):2061-2068. doi: 10.1007/s10096-019-03648-2. Epub 2019 Aug 8.

Supplemental Content

Loading ...
Support Center